Thursday, July 10, 2025
HomeNews

News

Pneumagen Announces First Patient Dosed in Phase 2 Proof of Concept

Pneumagen, a clinical stage biotech company developing Neumifil, an intranasal, broad-spectrum antiviral treatment to prevent or, if infected reduce and manage viral respiratory tract...

Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed

Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company has developed a Peptide Docking Vehicle (PDoV™)...

Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study

Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company developing novel drugs for cancer, fibrosis and inflammation, announced it has received notice from the...

European Medicines Agency Grants Orphan Drug Designation to INBRX-109

Inhibrx, Inc., a biotechnology company with four clinical programs in development and a strong emerging pipeline, announced that the European Commission ("EC"), based on...

Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer

Anixa Biosciences, Inc. a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced that, in conjunction with its partner...
0FansLike
0FollowersFollow
spot_img

Hot Topics